EUVIMEDEUVIMED entdecken
Crossref

Radiomics-based prediction of HCC response to atezolizumab/bevacizumab

I. Rodriguez, A. Vellala, T. Itzel, J. Daza, M. Vácha, D.-H. Chang, M. Debic, M. T. Dill, M. Seidensticker, J. Mayerle, S. Munker, S. O. Schoenberg und 14 weitere

Zeitschrift für Gastroenterologie · 01.09.2024 · 62 (09) · e735-e736

DOI: 10.1055/s-0044-1789914 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.09.2024. Verfasst von I. Rodriguez und 25 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atezolizumab/bevacizumab has emerged as a breakthrough therapy for advanced hepatocellular carcinoma (HCC). However, as not all patients respond equally to immunotherapy, predicting treatment response remains an important issue in order to stratify and optimize treatment.

Methods

We investigated 103 HCC patients treated with atezolizumab/bevacizumab, and either disease control (DC) or progressive disease (PD) based on their response to therapy. Radiomics features were extracted from baseline MRI scans. Predictive models using radiomics variables and clinical variables were developed separately and ultimately also integrated to create a composite predictive model. Hyper-parameter tuning and stratified K Fold cross-validation were employed to optimize predictive accuracy and ensure robustness.

Results

While clinical parameters alone showed limited predictive accuracy (40% accuracy, AUC 0.62), radiomics features demonstrated modest performance (55% accuracy, AUC 0.79). However, the hybrid model combining both clinical and radiomics data exhibited significantly improved predictive efficacy, with an overall accuracy of 88% and an AUC of 0.98 for predicting disease progression.

Conclusion

Machine learning significantly enhances the development of hybrid models capable of predicting response to atezolizumab/bevacizumab by leveraging both clinical and radiomics features. Our hybrid model clearly outperformed models solely based on clinical/serological parameters or radiomics features. Publication History Article published online: 26 September 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Rodriguez, I., Vellala, A., Itzel, T., Daza, J., Vácha, M., Chang, D., Debic, M., Dill, M. T., Seidensticker, M., Mayerle, J., Munker, S., Schoenberg, S. O., Müller, L., Galle, P. R., Weinmann, A., Tamandl, D., Pinter, M., Scheiner, B., Pech, M., …, & Froelich, M. F. (2024). Radiomics-based prediction of HCC response to atezolizumab/bevacizumab. Zeitschrift für Gastroenterologie, 62(09), e735-e736. https://doi.org/10.1055/s-0044-1789914

Vancouver

Rodriguez I, Vellala A, Itzel T, Daza J, Vácha M, Chang D, et al. Radiomics-based prediction of HCC response to atezolizumab/bevacizumab. Zeitschrift für Gastroenterologie. 2024;62(09):e735-e736. doi:10.1055/s-0044-1789914

BibTeX
@article{Rodriguez2024,
  author = {Rodriguez, I. and Vellala, A. and Itzel, T. and Daza, J. and Vácha, M. and Chang, D.-H. and Debic, M. and Dill, M. T. and Seidensticker, M. and Mayerle, J. and Munker, S. and Schoenberg, S. O. and Müller, L. and Galle, P. R. and Weinmann, A. and Tamandl, D. and Pinter, M. and Scheiner, B. and Pech, M. and Sinner, F. and Keitel, V. and Venerito, M. and Santamaria, L. and Ebert, M. P. and Teufel, A. and Froelich, M. F.},
  title = {Radiomics-based prediction of HCC response to atezolizumab/bevacizumab},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2024},
  volume = {62},
  number = {09},
  pages = {e735--e736},
  doi = {10.1055/s-0044-1789914}
}
Kostenlos starten →